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Sir,
We thank Drs Pickering-Brown and Hardy for their com-
ment and interest in our recent article regarding the role of
SIGMAR1 in motor neuron biology. In our study, we used
a combination of in vivo and in vitro models of loss-of-
function of SIGMAR1 to provide new insight into the role
of endoplasmic reticulum-mitochondria contacts, calcium
homeostasis and mitochondrial function for maintenance
of motor neuron integrity (Bernard-Marissal et al., 2015).
Regarding the comment from Pickering-Brown and Hardy,
it is important to reiterate that our interest in the role of
SIGMAR1 in motor neurons was based on multiple previ-
ous studies showing that (i) the Sigmar1 knock-out mouse
presents motor disabilities (Langa et al., 2003; Mavlyutov
et al., 2010); (ii) SIGMAR1 is highly expressed in motor
neurons (Mavlyutov et al., 2010); (iii) stimulation of
SIGMAR1 function via its agonists Pre-084 is neuroprotec-
tive in a model of motor neuron disease (Mancuso et al.,
2012); (iv) that SIGMAR1 is dysregulated in tissues from
patients with amyotrophic lateral sclerosis (ALS) (that did
not show C9orf72 expansion) (Prause et al., 2013); and
(v) that mutations in SIGMAR1 are implicated in
frontotemporal lobar degeneration co-occurring with ALS
(FTLD-ALS) (Luty et al., 2010) and in juvenile ALS (Al-Saif
et al., 2011); as representative reports.
Some of the genetic data, which are the core of the com-
ment from Pickering-Brown and Hardy, were recently re-
evaluated based on the discovery that affected individuals
from the family originally reported by Luty and col-
leagues carry, in addition to the 3’ UTR SIGMAR1 variant,
also the C9orf72 repeat expansion (Dobson-Stone et al.,
2013). The unrelated case with SIGMAR1 variant also re-
ported by Luty and colleagues, however, does not carry the
C9orf72 repeat expansion (Dobson-Stone et al., 2013). Also,
oligogenic aetiology was previously suggested in some ALS
cases carrying the C9orf72 repeat expansion (Lattante et al.,
2015).
We anticipate that further genetic studies will help to
provide additional insight into the contribution of
SIGMAR1 to motor neuron disease. In the meantime,
the characterization of the role of SIGMAR1 in motor
neurons is already helping us to unravel their biology and
pathophysiology.
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